Titolo:  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists
Data di pubblicazione:  2014
Numero degli autori:  2
Lingua:  Inglese
Presenza coautori internazionali:  no
Volume:  25
Fascicolo:  4
Pagina iniziale:  392
Pagina finale:  401
Numero di pagine:  10
Digital Object Identifier (DOI):  http://dx.doi.org/10.1007/s12640-013-9446-8
Codice identificativo Pubmed:  24323318
Codice identificativo Scopus:  2-s2.0-84898829025
Codice identificativo ISI:  WOS:000334173200007
URL:  http://link.springer.com/article/10.1007%2Fs12640-013-9446-8
Abstract:  Animal models of motor dysfunction constitute the basis for the screening of new drugs with potential efficacy in diseases characterized by motor impairment, such as Parkinson’s Disease (PD). Taking adenosine A2A receptor antagonists as an example of a new class of drugs for PD, the review will examine the most utilized rodent models of motor impairment and the results reported in the literature with this class of drugs. The results obtained so far in rodent models of PD suggested that A2A receptor antagonists might have symptomatic therapeutic efficacy in PD. They may ameliorate initiation of movement, gait and muscle rigidity, sensorimotor integration deficits, and tremor. Moreover, A2A receptor antagonists when administered with a low sub-threshold dose of l-DOPA potentiated its efficacy. However, the clinical trials so far performed have evaluated their efficacy in the “ON/OFF” of PD patients with motor complications, showing a limited efficacy of this class of drug. Therefore, on one hand, animal models of PD might have a limited validity; on the other hand, clinical trials should explore the efficacy of A2A receptor antagonists on a broader range of parkinsonian conditions.
Parole Chiave:  Parkinson's disease; Rodent models; Catalepsy; 6-hydroxydopamine lesion; A2A receptor antagonists; Adenosine
Tipologia: 1.1 Articolo in rivista

File in questo prodotto:
File Descrizione Tipologia Licenza  
Pinna-Morelli 2014 NeuroTox.pdf  versione editoriale Administrator   Richiedi una copia

Questionario e social

Condividi su: